Transbilayer phospholipids molecular imaging

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-14

  Belhocine, Tarik Z ^a   Prato, Frank S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Molecular imaging; PET CT; Phospholipids; SPECT CT

Indexed keywords

ARSENICUM BAVITUXIMAB AS 76; ARSENICUM BAVITUXIMAB AS 77; BAVITUXIMAB; CARBON CHOLINE C 11; CARBON DIACYLGLYCEROL C 11; CARBON ETHANOLAMINE C 14; CARBON INOSITOL C 11; CARRIER PROTEINS AND BINDING PROTEINS; CHOLINE; FLUOROCHOLINE F 18; HYPERICIN; IODINE HYPERICIN I 131; LACTADHERIN; LANCOVUTIDE; LIPID; LIPOCORTIN 5; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE BINDING PEPTIDE 6; PHOSPHATIDYLSERINE CHOLINOPHOSPHOLIPID; PHOSPHOLIPID; RADIOPHARMACEUTICAL AGENT; SPHINGOMYELIN; SYNAPTOTAGMIN I; TECHNETIUM HYDRAZINONICOTINAMIDE ANNEXIN V TC 99M; TECHNETIUM HYDRAZINONICOTINAMIDE LACTADHERIN TC 99M; TECHNETIUM HYPERICIN TC 99M; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CELL MEMBRANE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG DESIGN; DRUG LABELING; DRUG TARGETING; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MEMBRANE BINDING; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84873902064     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-17     Document Type: Review

References (108)

1. Jain KK: Personalized medicine. Curr Opin Mol Ther 2002, 4:548-558, Review.
2. Basu S: Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol 2010, 7:665-668.
3. Hoffman JM, Gambhir SS: Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007, 244:39-47, Review.
4. Anderson CJ: A new vision for the MICoE. J Nucl Med 2010, 51, 19N, 24N.
5. Hnatowich DJ: Observations on the role of nuclear medicine in molecular imaging. J Cell Biochem Suppl 2002, 39:18-24, Review.
6. Pappas V: Renewed energy for nuclear medicine and molecular imaging. J Nucl Med 2011, 52:20N.
7. Pomper MG, Gelovani JG: Molecular Imaging in Oncology Informa Healthcare USA, Inc; 2008.
8. Mankoff ADavid: A definition of molecular imaging. J Nucl Med 2007, 48:18N, 21N.
9. Reubi JC, Maecke HR: Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738, Review.
10. Tait JF: Imaging of Apoptosis. J Nucl Med 2008, 49:1573-1576.
11. Anderson CJ, Bulte JW, Chen K, Chen X, Khaw BA, Shokeen M, Wooley KL, VanBrocklin HF: Design of targeted cardiovascular molecular imaging probes. J Nucl Med 2010, 51(Suppl 1):3S-17S.
12. Eckelman WC, Reba RC, Kelloff GJ: Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 2008, 13:748-759.
13. Vance JE, Steenbergen R: Metabolism and functions of phosphatidylserine. Prog Lipid Res 2005, 44:207-234, Review.
14. Ulrich AS: Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002, 22:129-150, Review.
15. Phillips WT, Goins BA, Bao A: Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:69-83, Review.
16. Singer SJ, Nicolson GL: The fluid mosaic model of the structure of cell membranes. Science 1972, 175:720-731.
17. Bagatolli LA, Ipsen JH, Simonsen AC, Mouritsen OG: An outlook on organization of lipids in membranes: searching for a realistic connection with the organization of biological membranes. Prog Lipid Res 2010, 49:378-389.
18. Vereb G, Szöllosi J, Matkó J, Nagy P, Farkas T, Vigh L, Mátyus L, Waldmann TA, Damjanovich S: Dynamic, yet structured: the cell membrane three decades after the Singer-Nicolson model. Proc Natl Acad Sci USA 2003, 100:8053-8058, Review.
19. Yamaji-Hasegawa A, Tsujimoto M: Asymmetric distribution of phospholipids in biomembranes. Biol Pharm Bull 2006, 29:1547-1553, Review.
20. Balasubramanian K, Schroit AJ: Aminophospholipid asymmetry: a matter of life and death. Annu Rev Physiol 2003, 65:701-734, Review.
21. Garcia-Manyes S, Redondo-Morata L, Oncins G, Sanz F: Nanomechanics of lipid bilayers: heads or tails? J Am Chem Soc 2010, 132:12874-12886.
22. van Meer G, Voelker DR, Feigenson GW: Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 2008, 9:112-124, Review.
23. Groves AM, Win T, Haim SB, Ell PJ: Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007, 8:822-830, Review.
24. Belhocine TZ, Blankenberg FG: The imaging of apoptosis with the radiolabelled annexin A5: a new tool in translational research. Curr Clin Pharmacol 2006, 1:129-137, Review.
25. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132, Review.
26. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G: Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004, 31:887-919, Review.
27. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A: Increased uptake of the apoptosis-imaging agent (99m) Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
28. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, Heidendal GA, Reutelingsperger CP: Past, present, and future of annexin A5: from discovery to clinical applications. J Nucl Med 2005, 46:2035-2050, Review.
29. Sarda-Mantel L, Coutard M, Rouzet F, Raguin O, Vrigneaud JM, Hervatin F, Martet G, Touat Z, Merlet P, Le Guludec D, Michel JB: 99mTc. annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:2153-2159.
30. Kartachova MS, Valdés Olmos RA, Haas RL, Hoebers FJ, van Herk M, Verheij M: 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun 2008, 29:39-44.
31. Vermeersch H, Ham H, Rottey S, Lahorte C, Corsetti F, Dierckx R, Steinmetz N, Van de Wiele C: Intraobserver, interobserver, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin V imaging in head and neck carcinoma. Cancer Biother Radiopharm 2004, 19:205-210.
32. Tait JF, Smith C, Levashova Z, Patel B, Blankenberg FG, Vanderheyden JL: Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med 2006, 47:1546-1553.
33. Zhao M, Zhu X, Ji S, Zhou J, Ozker KS, Fang W, Molthen RC, Hellman RS: 99mTc-labelled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006, 47:1367-1374.
34. Zhu X, Li Z, Zhao M: Imaging acute cardiac cell death: temporal and spatial distribution of 99mTc-labelled C2A in the area at risk after myocardial ischemia and reperfusion. J Nucl Med 2007, 48:1031-1036.
35. Fang W, Wang F, Ji S, Meier HT, Hellman RS, Brindle KM, Davletov B, Zhao M: SPECT imaging of myocardial infarction using 99mTc-labelled C2A domain of synaptotagmin I a porcine ischemia-reperfusion model. Nucl Med Biol 2007, 34:917-923.
36. Zhu X, Migrino RQ, Hellman RS, Brahmbhatt T, Zhao M: Early uptake of 99mTc-C2A: in the acute phase of myocardial infarction as a prognostic indicator for follow-up cardiac dysfunction. Nucl Med Commun 2008, 29:764-769.
37. Wang F, Fang W, Zhao M, Wang Z, Ji S, Li Y, Zheng Y: Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study. Nucl Med Biol 2008, 35:359-364.
38. Wang F, Fang W, Zhang MR, Zhao M, Liu B, Wang Z, Hua Z, Yang M, Kumata K, Hatori A, Yamasaki T, Yanamoto K, Suzuki K: Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labelled C2A domain of synaptotagmin I. J Nucl Med 2011, 52:592-599.
39. Tavaré R, Torres Martin De Rosales R, Blower PJ, Mullen GE: Efficient sitespecific radiolabeling of a modified C2A domain synaptotagmin I with [99mTc(CO)3]+: a new radiopharmaceutical for imaging cell death. Bioconjug Chem 2009, 20:2071-2081.
40. Ran S, Downes A, Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002, 62:6132-6140.
41. Ran S, Thorpe PE: Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002, 54:1479-1484.
42. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE: Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005, 11:1551-1562.
43. Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, Watkins L, Kodibagkar VD, O'Kelly S, Kulkarni P, Antich PP, Hermanne A, Rösch F, Mason RP, Thorpe PE: Vascular imaging of solid tumors in rats with a radioactive arsenic-labelled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008, 14:1377-1385.
44. Chopra A: [74]-Labeled monoclonal antibody against anionic phospholipids. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
45. Song S, Xiong C, Zhou M, Lu W, Huang Q, Ku G, Zhao J, Flores LG Jr, Ni Y, Li C: Small-animal PET of tumor damage induced by photothermal ablation with 64cu-bis-dota-hypericin. J Nucl Med 2011, 52:792-799.
46. Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM: First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006, 33:595-601.
47. Fonge H, Vunckx K, Wang H, Feng Y, Mortelmans L, Nuyts J, Bormans G, Verbruggen A, Ni Y: Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J 2008, 29:260-269.
48. Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, Huang D, Nuyts J, Yu J, Meng B, Bormans G, Fang Z, de Witte P, Li Y, Verbruggen A, Wang X, Mortelmans L, Xu K, Marchal G, Ni Y: A dual-targeting anticancer approach: soil and seed principle. Radiology 2011, 260:799-807.
49. Chopra A: [99mTc]-Mercaptoacetyldiglycyl-1,5-diaminopentylene hypericincarboxamide. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
50. Fonge H, Jin L, Wang H, Bormans G, Ni Y, Verbruggen A: Synthesis and preliminary biological evaluation of a 99mTc-labelled hypericin derivative as a necrosis avid imaging agent. J Label Comp Radiopharm 2008, 51:33-40.
51. Häggqvist B, Näslund J, Sletten K, Westermark GT, Mucchiano G, Tjernberg LO, Nordstedt C, Engström U, Westermark P: Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci USA 1999, 96:8669-8674.
52. Hou J, Fu Y, Zhou J, Li W, Xie R, Cao F, Gilbert GE, Shi J: Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox Sang 2011, 100:187-195.
53. Schutters K, Reutelingsperger C: Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 2010, 15:1072-1082, Review.
54. Shi J, Shi Y, Waehrens LN, Rasmussen JT, Heegaard CW, Gilbert GE: Lactadherin detects early phosphatidylserine exposure on immortalized leukemia cells undergoing programmed cell death. Cytometry A 2006, 69:1193-1201.
55. Waehrens LN, Heegaard CW, Gilbert GE, Rasmussen JT: Bovine lactadherin as a calcium-independent imaging agent of phosphatidylserine expressed on the surface of apoptotic HeLa cells. J Histochem Cytochem 2009, 57:907-914.
56. Falborg L, Waehrens LN, Alsner J, Bluhme H, Frøkiaer J, Heegaard CW, Horsman MR, Rasmussen JT, Rehling M: Biodistribution of 99mTc-HYNIC lactadherin in mice-a potential tracer for visualizing apoptosis in vivo. Scand J Clin Lab Invest 2010, 70:209-216.
57. Xiong C, Brewer K, Song S, Zhang R, Lu W, Wen X, Li C: Peptide-based imaging agents targeting phosphatidylserine for the detection of apoptosis. J Med Chem 2011, 54:1825-1835.
58. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR: Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002, 168:273-280.
59. Leung K: [11C]Choline. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011.
60. Leung K: [18F]Fluorocholine. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011.
61. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE: Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002, 43:92-96.
62. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I: PET with (18) F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010, 37:2188-2193.
63. Chiti A, Picchio M: The rising PET: the increasing use of choline PET/CT in prostate cancer. Eur J Nucl Med Mol Imaging 2011, 38:53-54.
64. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN: The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011, 59:51-60.
65. Kwee SA, Coel MN, Lim J, Ko JP: Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging 2004, 14:285-289.
66. Hara T, Kondo T, Hara T, Kosaka N: Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003, 99:474-479.
67. Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN: Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology 2007, 244:557-565.
68. Lam WW, Ng DC, Wong WY, Ong SC, Yu SW, See SJ: Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-Early experience. Clin Neurol Neurosurg 2011, 113:156-161.
69. Kuang Y, Salem N, Tian H, Kolthammer JA, Corn DJ, Wu C, Wang F, Wang Y, Lee Z: Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with on vivo metabolic studies. J Nucl Med 2011, 52:98-106.
70. Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z: PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-d-deoxyglucose, 6-deoxy-6[18F] fluoro-d-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging 2009, 53:144-156.
71. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, Kaji M, Ohkawa M: Detection of hepatocellular carcinoma using 11Ccholine PET: comparison with 18F-FDG PET. J Nucl Med 2008, 49:1245-1248.
72. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O: PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006, 33:1285-1289.
73. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O: Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18FFDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010, 51:1699-1706.
74. Leung K: [11C]Acetate. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
75. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, Takahashi N, Welch MJ, Fujibayashi Y: Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001, 28:117-122.
76. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G: Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003, 302:898-903.
77. Leung K: [11C]Acetoacetate. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
78. Leung K: 2-[18F]Fluoroacetate. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010, 2007 Mar 22 [updated 2008 Jun 24].
79. Lindhe O, Sun A, Ulin J, Rahman O, Långström B, Sörensen J: [(18)F] Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 2009, 36:1453-1459.
80. Jadvar H: Prostate cancer: PET with 18F-FDG, 18F. or 11C-Acetate, and 18F. or 11C-choline. J Nucl Med 2011, 52:81-89.
81. Liu RS: Clinical applications of C-11-acetate in oncology [abstract]. Clin Positron Imaging 2000, 3:185.
82. Marik J, Ogasawara A, Martin-McNulty B, Ross J, Flores JE, Gill HS, Tinianow JN, Vanderbilt AN, Nishimura M, Peale F, Pastuskovas C, Greve JM, van Bruggen N, Williams SP: PET of glial metabolism using 2-18Ffluoroacetate. J Nucl Med 2009, 50:982-989.
83. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, Siegel BA, Welch MJ: 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11Cacetate. J Nucl Med 2007, 48:420-428.
84. Matthies A, Ezziddin S, Ulrich EM, Palmedo H, Biersack HJ, Bender H, Guhlke S: Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004, 31:797.
85. Authier S, Tremblay S, Dumulon V, Dubuc C, Ouellet R, Lecomte R, Cunnane SC, Benard F: [(11)C] Acetoacetate utilization by breast and prostate tumors: a PET and biodistribution study in mice. Mol Imaging Biol 2008, 10:217-223.
86. Pifferi F, Tremblay S, Plourde M, Tremblay-Mercier J, Bentourkia M, Cunnane SC: Ketones and brain function: possible link to polyunsaturated fatty acids and availability of a new brain PET tracer, 11C-acetoacetate. Epilepsia 2008, 49(Suppl 8):76-79, Review.
87. Bentourkia M, Tremblay S, Pifferi F, Rousseau J, Lecomte R, Cunnane S: PET study of 11C-acetoacetate kinetics in rat brain during dietary treatments affecting ketosis. Am J Physiol Endocrinol Metab 2009, 296:E796-801.
88. Vance JE: Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008, 49:1377-1387, Review.
89. Marconescu A, Thorpe PE: Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochim Biophys Acta 2008, 1778:2217-2224.
90. Stafford JH, Thorpe PE: Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. Neoplasia 2011, 13:299-308.
91. Leung K: 99mTc-(Hydrazinonicotinic acid-duramycin)(tricine)(TPPTS). Molecular Imaging and Contrast Agent Database (MICAD) [Internet] Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
92. Zhao M, Li Z, Bugenhagen S: 99mTc-labelled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 2008, 49:1345-1352.
93. Mintz A, Wang L, Ponde DE: Comparison of radiolabeled choline and ethanolamine as probe for cancer detection. Cancer Biol Ther 2008, 7:742-747.
94. Vance JE, Vance DE: Phospholipid biosynthesis in mammalians cells. Biochem Cell Biol 2004, 82:113-128, Review.
95. Imahori Y, Fujii R, Ueda S, Matsumoto K, Wakita K, Ido T, Nariai T, Nakahashi H: Membrane trapping of carbone-11-labelled 1,2-diacylglycerols as a basic concept for assessing phosphatidylinositol turnover in neurotransmission process. J Nucl Med 1992, 33:413-422.
96. Sasaki T, Ogihara-Umeda I, Kojima S, Nishigori H: Sequential enzymatic synthesis and biodistribution of radiolabelled inositol and inositol analogs. Int J Rad Appl Instrum A 1991, 42:97-101.
97. Fujii R, Ueda S, Kanatsuna T, Imahori Y, Ido T, Wakita K, Horii H, Yagyu T, Higashi N, Mabuchi H, Ohmori Y: [Carbon-11 labelled diacylglycerol for signal transduction imaging by positron CT: evaluation of the quality and safety for clinical use]. Kaku Igaku 1995, 32:191-198, Japanese.
98. Imahori Y, Fujii R, Ueda S, Ohmori Y, Wakita K, Matsumoto K: Phosphoinositide turnover imaging linked to muscarinic cholinergic receptor in the central nervous system by positron emission tomography. J Nucl Med 1993, 34:1543-1551.
99. Imahori Y, Ohmori Y, Fujii R, Matsumoto K, Ueda S: Rapid incorporation of carbon-11-labeled diacylglycerol as a probe of signal transduction in glioma. Cancer Res 1995, 55:4225-4229.
100. Kondo M, Imahori Y, Mori S, Ueda Y, Fujii R, Nakajima K: Aberrant plasticity in Alzheimer's disease. Neuroreport 1999, 10:1481-1484.
101. Matsumoto K, Imahori Y, Fujii R, Ohmori Y, Sekimoto T, Ueda S, Mineura K: Evaluation of phosphoinositides turnover on ischemic human brain with 1-[1-11]-butyryl-2-palmitoyl-rac-glycerol using PET. J Nucl Med 1999, 40:1590-1594.
102. Imahori Y, Fujii R, Kondo M, Ohmori Y, Nakajima K: Neural features of recovery from CNS injury revealed by PET in human brain. Neuroreport 1999, 10:117-121.
103. Chida M, Kagaya Y, Imahori Y, Namiuchi S, Fujii R, Fukuchi M, Takahashi C, Tezuka F, Ido T, Shirato K: Visualization of myocardial phosphoinositide turn over with 1-[1-(11)C]-butyryl-2-palmitoyl-rac-glycerol in rats with myocardial infarction. J Nucl Med 2000, 41:2063-2068.
104. Kagaya Y, Chida M, Imahori Y, Fujii R, Namiuchi S, Takeda M, Yamane Y, Otani H, Watanabe J, Fukuchi M, Tezuka F, Ido T, Shirato K: Effect of angiotensin converting enzyme inhibition on myocardial phosphoinositides metabolism visualised with 1-[1-11C]-butyryl-2-palmitoyl-rac-glycerol in myocardial infarction in the rat. Eur J Nucl Med Mol Imaging 2002, 29:1516-1522.
105. Otani H, Kagaya Y, Imahori Y, Yasuda S, Fujii R, Chida M, Namiuchi S, Takeda M, Sakuma M, Watanabe J, Ido T, Nonogi H, Shirato K: Myocardial 11C-diacylglycerol accumulation and left ventricular remodelling in patients after myocardial infarction. J Nucl Med 2005, 46:553-559.
106. Chida M, Kagaya Y, Nagata S, Mukoyoshi M, Namiuchi S, Yamane Y, Ishide N, Watanabe J, Takahashi T, Ido T, Shirato K: [18F] labelled diacylglycerol analogue as a potential agent to trace myocardial phosphoinositide metabolism. Nucl Med Biol 2001, 28:815-819.
107. Ogihara-Umeda I, Kojima S: Increased delivery of gallium-67 to tumors using serum-stable liposomes. J Nucl Med 1988, 29:516-523.
108. Kostenikov NA, Fadeev NP, Serzhanina VA, Koresakova LN, Rozenberg OA: [An experimental study of the tumor affinity of gallium-67-labelled sphyngomyelin liposomes]. Vopr Onkol 1992, 38:1080-1084, Russian.